The prognosis of breast cancer patients in relation to the oestrogen receptor status of both primary disease and involved nodes. by Castagnetta, L. et al.
Br. J. Cancer (1992), 66, 167-170
© Macmillan Press
The prognosis of breast cancer patients in relation to the oestrogen
receptor status of both primary disease and involved nodes
L. Castagnettal'3, A. Traina2, G. Carruba"4, E. Fecarotta', G. Palazzotto2 & R. Leake4
'Hormone Biochemistry Laboratory, University School ofMedicine, Policlinico, 90127 Palermo, 2Cancer Hospital Centre 'M.
Ascoli' USL 58, Palermo, 3Molecular Endocrinology and Experimental Oncology Units ofthe Scientific Institutefor Cancer in
Genova (Palermo branch), Italy and 4Department ofBiochemistry, University ofGlasgow, Glasgow G12 8QQ, UK.
Summary Nodal involvement is accepted as the best single marker of prognosis in breast cancer. However,
there is little information on the sub-division of node-positive patients according to the oestrogen receptor
status of the nodal tissue. We have previously reported (Eur. J. Ca. 1987, 23, 31) that, in almost all cases,
involved nodes are only oestrogen receptor positive (ER+) in patients whose primary tumours are uniformly
ER+. This paper presents clinical follow-up on a larger group of patients with node positive breast cancer.
For each patient, both soluble and nuclear receptor concentrations were determined in three separate parts of
the primary tumour and in at least one involved node (we have previously defined tumours which contained
ER in all six fractions of the primary as HS+ +, those lacking receptor in some fractions as HS+ - and
wholly receptor negative tumours as HS- -). Median follow-up time was 71.5 months. As expected, patients
whose tumours were HS + + had a significant (P <0.008) survival advantage. More importantly, patients with
ER in both the soluble and nuclear fractions of their involved nodes survived significantly (P<0.003) longer
than those with ER- nodes. Thus, full oestrogen receptor status of involved nodes will give sufficient
prognostic information when adequate primary tissue is not available.
The presence of involved nodes, at the time of initial diag-
nosis of breast cancer, is generally recognised to be an indica-
tion of poor prognosis. For this reason, aggressive therapy is
often considered for all such patients. However, the biology
of the disease is such that some patients, presenting with
node positive disease, will relapse quickly whilst others sur-
vive for several years. If these two sub-groups could be
separated on the basis of some marker, then therapy selection
would be more specific. In an earlier paper (Castagnetta et
al., 1987), we have compared the oestrogen receptor (ER)
status in different sections of the primary, together with that
of the involved node(s). Receptor content was measured in
different areas of the same primary because various studies
have shown that there can be heterogeneity in the receptor
status across a breast (Silverswaard et al., 1980; Pertschuk et
al., 1985) or endometrial cancer (Castagnetta et al., 1983).
We have previously (Castagnetta et al., 1987) designated
tumours as being of hormone sensitive (HS) status + + if
both soluble and nuclear fractions from all areas biopsied
were oestrogen receptor positive, HS + - if some areas were
positive and others negative and HS - - when all areas
biopsied were negative. Our previous studies have shown that
a heterogeneous primary (+ -) was much more likely to give
rise to receptor negative nodes. Indeed, it was found (Cas-
tagnetta et al., 1987) that primary tumours which were
uniformly receptor positive (+ +), were highly likely (27 out
of 29) to give rise to receptor positive nodes, whereas
heterogeneous (+ -) primaries were most likely (17 out of
20) to give rise to receptor negative nodes.
HS status may well reflect the biology of the tumour. If
this is the case, then the decision on appropriate therapy for
an individual patient may be influenced by the HS status of
the disease. These results might also direct the treatment of
patients with involved nodes, in that uniformly receptor
positive primaries (HS + +) might be assumed to reflect
hormone-sensitive metastatic disease, whereas patients with
heterogeneous primaries (HS + -) might be treated as hav-
ing disease with lower hormone sensitivity.
Current practice is strongly influenced by the meta-analysis
of early breast cancer trials (Early Breast Cancer Trialists'
Collaborative Group, 1988) and, in many countries, node-
involved, premenopausal patients are all treated with first-
line chemotherapy. Information which argues against such
blanket treatment, comes from the multi-centre (GROCTA)
study (Boccardo et al., 1990) in Italy. This showed that node
positive, oestrogen receptor positive breast cancer patients
have both improved disease-free and total survival when
treated with hormone-plus-chemotherapy or hormone ther-
apy alone, when compared with chemotherapy alone. These
data suggest that hormone therapy has a positive advantage
even in the therapy of premenopausal, node-positive patients.
To further explore the biological implications of these obser-
vations, we now report follow up on a group of 74 breast
cancer patients with node-involved disease, on whom full
receptor data is available.
Patients and methods
A study was set up of 74 consecutive breast cancer patients
who, on presentation to the Cancer Hospital in Palermo,
were found to have involved axillary nodes, but no other
confirmed overt metastases. Both N-l (n = 66) and N-2
(n = 8) patients were included. All patients underwent Patey-
modified radical mastectomy. The mean number of nodes
from each patient that was pathologically examined was
13 ± 7 (range 4-33 - only seven patients had less than ten
nodes examined) and the mean number of histologically
involved nodes was 7.8 ± 7. The proportion of nodes investi-
gated that were found to contain malignant cells was similar
in all three groups of patients (see later for details) being
54% for those HS + +, 59% for (+ -) and 62% for (--).
Of the eight patients with N-2 nodes, four had (--)
primaries, three (+ -) and one (+ +).
Oestrogen receptor content was determined immediately on
the fresh tissue in both a single, involved node (randomly
selected by the pathologist from those nodes which were
histologically malignant) and in three different parts of each
primary (designated central, intermediate and peripheral). In
eight cases, three separate nodes were assayed in order to
establish the consistency of receptor status. Receptor assay
was carried out using our standard seven point Scatchard
plot analysis over the range 1-10 x 10-I0 M 3H-oestradiol,
with non-specific binding being calculated using competition
with 100-fold diethyl stilbestrol at two concentrations of
oestradiol (Leake & Habib, 1987). For all receptor assays
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reported here, adequate quantities of histologically malignant
cells were seen in a parallel section.
As previously described, patients were allocated to one of
the three HS classes according to the distribution of both
soluble and nuclear oestrogen receptor across their primary
disease. If the ER status was positive (i.e. Scatchard analysis
showed oestrogen receptor at more than 12 fmol mg-' cyto-
sol protein (soluble receptor) and more than 250 fmol mg-'
DNA (nuclear receptor) in each of the three portions of the
primary tumour assayed, then the patient was allocated to
the (+ +) group. The HS classification system is summarised
in Table I. Patients whose nodes contained both soluble and
nuclear oestrogen receptor were designated ER+ (n = 31),
the remainder were designated ER- (n = 43), although 15 of
these 43 nodes did show some ER in only one fraction - the
details of these are given in the Results section.
Treatment of patients is summarised in Table II. Patients
were followed up initially at three monthly intervals. Those
remaining disease-free for more than 2 years were then seen
at six monthly intervals. Median follow-up time is 71.5
months (range 48-125 months).
DNA content was determined by a modification of the
Burton method (Katzenellenbogen & Leake, 1974) and pro-
tein by the standard Lowry method (Lowry et al., 1951).
Life table analysis was performed using the Kaplan-Meier
method (Kaplan & Meier, 1958) and statistical comparison
performed using the Mantel and Haenszel procedure (Mantel
& Haenszel, 1959).
Results
Of the 30 patients who were classified as HS + + on the
basis of the uniform presence of ER across the primary
biopsy, 28 had nodes which also contained both soluble and
nuclear receptor. For the remaining two patients, no oestro-
gen receptor was detectable in either the soluble or the
nuclear fraction from the involved node. Three patients with
(+ -) primaries showed both soluble and nuclear oestrogen
receptor in their nodes. Of the remaining 21 patients whose
primaries were (+ -), 14 had nodes in which oestrogen
receptor was undetectable (or below cut-off limits) in both
soluble and nuclear fractions of the node, five were found to
have only nuclear receptor and two only soluble receptor.
Table I Summary ofclassification ofprimary breast cancers according
to distribution of oestrogen receptor (HS status)
Section I Section 2 Section 3
ER, ERn ER, ERn ERs ERn HS Group
+ + + + + + (+ +)
+ - +' + + + (+-)
ER assays were carried out in both the soluble (ERJ) and nuclear
(ER,) fractions ofeach ofthree separate sections oftheprimary tumour.
Any patient whose tumour contains ER in some (one) fractions but not
in other fractions of the primary tumour is, of course, designated HS
(+ -)
Table II Treatment received by patients
Treatment
HS status Menopausal status Tam CMF CMF+ Tam
(++) Pre(n=11) 0 5 6
(n = 30) Post (n= 19) 13 0 6
(+-) Pre (n=11) 0 11 0
(n =24) Post (n=13) 2 7 4
(--) Pre (n=11) 0 11 0
(n =20) Post (n =9) 2 7 0
Patients wereclassified into HS status asdefinedinTable I. Treatment
received was tamoxifen alone (Tam), CMF alone (CMF) or the
combination ofCMF + Tam. The CFM protocol has been extensively
described by Bonadonna et al. (1977) and thejustification for including
tamoxifen intheregimen forpre-menopausal patientsisgivenin a recent
paper of Early Breast Cancer Trialists' Collaborative Group (1992).
None of the 20 patients with (- -) primaries was found to
have both soluble and nuclear receptor in their nodes
although, five did show some nuclear receptor and three
some soluble receptor. The concordance of HS status of the
primary with ER status of the involved node from each
patient is summarised in Table III. Overall, the mean recep-
tor concentrations in each fraction were similar to those
reported in our earlier, smaller study (Castagnetta et al.,
1987).
The patient characteristics, when classified according to the
receptor distribution within their primary disease (HS status),
are shown in Table IV, those according to the receptor status
of their involved nodes is shown in Table IV. It can be seen
that the mean age in the three groups was similar, although
patients with uniformly receptor negative primaries (HS
- -) tended to be slightly younger. Correspondingly, the
mean post-menopausal age is also slightly less in this group.
This is not unexpected since, the proportion of oestrogen
receptor positive patients increases with age (Hawkins et al.,
1980). Nevertheless, it is important to remember that, in all
three HS groups, a similar proportion of the nodes inves-
tigated was found to contain tumour. In the eight cases
where receptor assays were carried out on three separate,
involved nodes from each patient, six sets of nodes were
self-consistent in status. Of the two in which differences were
observed, one set of nodes, obtained from a (+ +) primary,
were all positive for nuclear receptor but one lacked signi-
ficant soluble receptor. In the second case, the primary was
(+ -) and the three nodes again all contained nuclear recep-
tor but two failed to demonstrate soluble receptor. Overall,
receptor distribution in different involved nodes from a single
patient appears to be uniform.
The follow-up of patients, relative to HS status of the
primary disease, is shown in Table Va and Figure 1, whilst
that relative to receptor status of involved nodes is shown in
Table Vb and Figure 2. Patients with (+ +) primary disease
Table III Comparison ofHS status ofthe primary with ER status of
the corresponding involved node
ER status ofnode
HS status ofprimary + - Total
++ 28 2 30
+- 3 21 24
-- 0 20 20
HS status (asdefined inTableI) reflectsdistribution ofERacross the
primary, whereas ERstatusofthenodeis(+)ifERwaspresentinboth
soluble and nuclear fraction from the node, and (-) ifER was absent
(or below threshold values) from either fraction.
Table IVa General characteristics of patients relative to oestrogen
receptor distribution (HS status) in the primary disease
(++) (+-) (--)
n=30 n=24 n=20
Mean age 54.0± 10.1 52.4± 12.9 49.8± 10.1
PM mean age 11.0±5.0 13.4±9.6 7.7±5.0
(n = 19) (n = 13) (n = 9)
PM = postmenopausal age; numbers in parentheses indicate patients
who were postmenopausal. HS status is defined in Table I. Values
represent mean± s.d.
Table IVb Characteristics ofpatients relative to the receptor status of
their involved nodes
ER+ ER-
(n = 31) (n = 43)
Mean age 55.2±11.2 50.4±10.7
PM age 13.1±8.1 9.7±6.1
(n = 19) (n = 21)
PM = postmenopausal age; numbers in parenthesis indicate patients
who were postmenopausal. ER- indicates that the involved node
assayedcontainedboth solubleand nuclearoestrogen receptors. Values
represent mean±s.d.ER STATUS OF INVOLVED NODES IN BREAST CANCER 169
TableVa Follow-updata, classified accordingto receptordistribution
in primary disease (HS status)
(++) (+-) (--)
n=30 n=24 n=20
Relapsed 14 12 14
(%) (47) (50) (70)
Dead 1Oa 12b 13
(%) (33) (50) (65)
aThree patients died from non cancer-related causes. bOne patient
died from non cancer-related cause.
Table Vb Follow-up data, classified according to receptor status of
nodes
ER+ ER- Total
n=31 n=43 n= 74
Relapsed 15 25 40
(%) (48) (58) (54)
Dead 12a 23b 35
(%) (39) (53) (47)
aThree patients died from non cancer-related causes. bOne patient
died from non cancer-related cause.
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Figure 1 Survival curves plotted for patients (n=30) whose
primary breast cancer contained both soluble and nuclear ER in
all three sections (HS + +) assayed (0--0) and those (n
= 20)
whose primary tumours were HS - - (--0) (P <0.008,
Kaplan-Meier method).
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Figure 2 Survival curves plotted for patients (n =31) whose
involved nodes contained both soluble and nuclear ER (0--0)
and those (n
= 43) whose involved nodes were ER- (0--0)
(P<0.003, Kaplan-Meier method).
have a significantly longer survival time (P<0.008) than do
those with (- -) primary disease. The survival curve for
patients with (+ -) disease was similar to that for patients
with (- -) disease. Patients with ER+ nodes survive
significantly longer than those with ER- nodes (P<0.003).
Discussion
In previous papers (Castagnetta et al., 1985; Castagnetta et
al., 1987; Castagnetta et al., 1989), we have distinguished
macro-heterogeneity of oestrogen receptor distribution (as
detected by changes in oestrogen receptor status, measured in
different parts of the tumour using the biochemical assay)
from the micro-heterogeneity, seen in most tumours when
stained with the Abbott immunocytochemical ERICA kit.
Our evidence suggests that multiple, biochemical determina-
tions give a better index of the biological potential of the
tumour than do single assays. Similar studies (measuring
only soluble oestrogen receptor) have also shown an advan-
tage to measuring receptor status in several different parts of
the tumour (Strauss et al., 1982; Castagnetta et al., 1983).
Nevertheless, there does seem to be, at least short term,
survival advantage for patients whose tumours are classified
oestrogen receptor positive by either biochemical assay of a
single biopsy (Mason et al., 1983; Howat et al., 1985) or by
the ERICA kit (Walker et al., 1988). However, the prognos-
tic value of ERICA is likely to be less than that of the
multiple biochemical assay simply because ERICA gives over
80% ofpatients as being receptor positive and only one-third
ofpatients respond (an appropriate clinical cut-off point may
be developed in the future).
Additionally, we (Castagnetta et al., 1987; Crawford et al.,
1987) and others (Raemakers et al., 1984) have shown that
the receptor status of primary and metastatic disease remains
the same in about 80% of cases and that disease recurring
after several years is still most likely to retain the receptor
status of the primary. However, it is clear that receptor
positivity is maintained in malignant disease only when both
soluble and nuclear oestrogen receptor can be demonstrated
throughout the tumour. Such macro-homogeneity is poten-
tially valuable for selecting therapy for patients with 'poor
prognosis' disease, such as those presenting with histo-
logically-involved nodes. In some centres, all such patients
would be treated with first-line chemotherapy, yet patients
with hormone-sensitive disease might benefit more from
endocrine therapy or combined endocrine/chemotherapy (see
GROCTA study - Boccardo et al., 1990).
The purpose of this study was to see whether patients with
uniform receptor positive (HS + +) primary disease and
receptor positive nodal disease had a real survival advantage
which would justify treating them differently from the
remainder of node-involved patients. The follow-up reported
here was for a median of 71.5 months (range 48-125). As
can be seen from the data in Table Va and Figure 1, there is
a significant survival advantage, over this time-span, for
patients with uniformly receptor positive primary disease.
The same is true when patients are compared on the basis of
receptor status of the involved nodes (Table Vb and Figure
2).
There is some bias in these data in that the (+ +) group of
patients was slightly older than the (- -) group. However, it
is still reasonable to suggest that patients with (+ +) disease
might be treated on the basis of having a significantly longer
life expectancy than is true for other patients presenting with
node-involved disease. Some of the survival advantage seen
in this study could be attributed to the different therapies
received. Therapy was mainly based on HS status and if the
conclusion is simply that greater survival is achieved by those
patients who respond to endocrine therapy, then these data
still make a case for using endocrine therapy in node-
involved patients with HS + + disease. Thus, HS status can
permit selective therapy even in patients with involved nodes,
as can ER status ofinvolved nodes, where receptor data were
not obtained on the primary disease. Such a selective ap-170 L. CASTAGNETTA et al.
proach has already been adopted in Palermo by the Cancer
Hospital Centre.
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